Co-administration of cisplatin and curcumin does not alter mood-associated behaviors

Basit Öğe Kaydı
dc.contributor.authorDemir, E. A.
dc.contributor.authorOz, M.
dc.contributor.authorAlp, M., I
dc.contributor.authorGergerlioglu, H. S.
dc.contributor.authorAtalik, Nurullahoglu K. E.
dc.contributor.authorYerlikaya, F. H.
dc.date.accessioned2024-02-23T14:37:59Z
dc.date.available2024-02-23T14:37:59Z
dc.date.issued2016
dc.departmentNEÜen_US
dc.description.abstractOBJECTIVES: Cisplatin (cis-diamminedichloroplatinum (II)) is a widely-used platinum-based chemotherapeutic agent which has dose-limiting side-effects. Also, the drug resistance is another instance that decreases treatment success in cisplatin chemotherapy. The growing body of evidence suggests that curcumin, a polyphenolic compound extracted from the spice turmeric, may exert synergistic effects and sensitize malign cells to cisplatin, while alleviating cytotoxicity-related side-effects. The present study was aimed to investigate mood-associated interactions between cisplatin and curcumin. MATERIALS AND METHODS: Thirty-four adult male Wistar albino rats were randomly assigned to four groups as control, curcumin (300 mg/kg/day, p.o. for 5 weeks), cisplatin (5 mg/kg/week, i.p. for 5 weeks), and curcumin plus cisplatin (same doses as above). The open field, elevated plus maze, and forced swim tests were engaged to evaluate mood-associated behaviors. RESULTS: We demonstrated that depression- and anxiety-like behaviors were not altered by the administration of curcumin along with the chronic cisplatin treatment. CONCLUSION: According to the results of the present study, we concluded that curcumin might be regarded as a safe adjuvant in cisplatin chemotherapy in terms of the mood-associated behaviors (Fig. 4, Ref 41).en_US
dc.identifier.doi10.4149/BLL_2016_021
dc.identifier.endpage111en_US
dc.identifier.issn0006-9248
dc.identifier.issn1336-0345
dc.identifier.issue2en_US
dc.identifier.pmid26830042en_US
dc.identifier.scopus2-s2.0-85014805323en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage106en_US
dc.identifier.urihttps://doi.org/10.4149/BLL_2016_021
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16317
dc.identifier.volume117en_US
dc.identifier.wosWOS:000371751300009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherComenius Univen_US
dc.relation.ispartofBratislava Medical Journal-Bratislavske Lekarske Listyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCisplatinen_US
dc.subjectCurcuminen_US
dc.subjectDepressionen_US
dc.subjectAnxietyen_US
dc.subjectLocomotionen_US
dc.subjectExplorationen_US
dc.titleCo-administration of cisplatin and curcumin does not alter mood-associated behaviorsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu